Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aspire Biopharma Holdings, Inc. (ASBP)
USD6.04
+0.01 (+0.17%)
US NASDAQ Healthcare Biotechnology
Address
23150 Fashion Drive 33928
Estero, FL, US
Estero, FL, US
CEO
Kraig T. Higginson
Website
aspirebiolabs.com
IPO
2025-02-20
CIK 1847345 ISIN US7389203057
Also trades on
NASDAQ Capital Market · ASBP (USD)
NASDAQ Global Market · ASBPW (USD)
Description
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.04
+0.01 (+0.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13M
Beta
0.16
Float Shares
77.7K
Free Float %
67.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.43% | +2.00% | -30.66% | -88.24% | -94.86% | -96.46% | -98.13% | -99.96% | -99.95% | -99.95% | -99.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6.04
Quality scores
Altman Z-Score
-7.68
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+9.9% Q1'26: -22.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-440,973.7% Q1'26: -10,716.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-312,017.0% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+116.7% Q1'26: -83.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: -0.08× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
1.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
-29 vs prev Q
New positions
0
Closed positions
29
Increased
0
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EP WEALTH ADVISORS, LLC | 62.7K +62.7K (+100.0%) | 8.27M +8.3M (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.28 +0.0% | 1 qtrs NEW |
| 2 | UBS GROUP AG | 2.51M +2.5M (+32,727.0%) | 332.0K +330.4K (+20,936.9%) | 0.03% +0.016 pp | 0.00% +0.000 pp | USD4.66 +13.3% | 4 qtrs — |
| 3 | CREWE ADVISORS LLC | 813.4K +— (+0.0%) | 107.3K -60.3K (-36.0%) | 0.01% -1.639 pp | 0.01% -0.007 pp | USD0.38 +1,289.5% | 4 qtrs — |
| 4 | JANE STREET GROUP, LLC | 688.1K +658.9K (+2,252.1%) | 90.8K +84.7K (+1,406.0%) | 0.01% -0.051 pp | 0.00% +0.000 pp | USD0.31 +1,603.2% | 4 qtrs — |
| 5 | VANGUARD GROUP INC | 428.6K +— (+0.0%) | 56.6K -31.7K (-35.9%) | 0.01% -0.863 pp | 0.00% +0.000 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 6 | OPTIVISE ADVISORY SERVICES LLC | 357.3K +93.8K (+35.6%) | 47.1K -7.2K (-13.2%) | 0.00% -0.530 pp | 0.03% -0.005 pp | USD0.39 +1,253.8% | 4 qtrs — |
| 7 | XTX TOPCO LTD | 265.5K +237.6K (+853.2%) | 35.0K +29.3K (+510.4%) | 0.00% -0.053 pp | 0.00% +0.001 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 247.6K -2.6K (-1.0%) | 32.7K -18.9K (-36.6%) | 0.00% -0.504 pp | 0.00% +0.000 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 9 | PROCYON ADVISORS, LLC | 232.7K -240.0K (-50.8%) | 30.7K -66.7K (-68.5%) | 0.00% -0.955 pp | 0.00% -0.004 pp | USD0.32 +1,550.0% | 4 qtrs — |
| 10 | ANTARA CAPITAL LP | 202.9K +— (+0.0%) | 26.8K -15.0K (-36.0%) | 0.00% -0.409 pp | 88.65% +80.121 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 11 | RESOLUTE ADVISORS LLC | 155.8K +73.0K (+88.2%) | 20.6K +3.5K (+20.5%) | 0.00% -0.166 pp | 0.01% +0.002 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 12 | THREE SEASONS WEALTH, LLC | 125.0K +50.0K (+66.7%) | 16.5K +1.0K (+6.7%) | 0.00% -0.150 pp | 0.00% +0.000 pp | USD0.27 +1,855.6% | 3 qtrs — |
| 13 | VIRTU FINANCIAL LLC | 108.8K +108.8K (+100.0%) | 14.0K +14.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.001 pp | USD5.28 +0.0% | 1 qtrs NEW |
| 14 | VERITION FUND MANAGEMENT LLC | 97.4K +97.4K (+100.0%) | 12.8K +12.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.28 +0.0% | 1 qtrs NEW |
| 15 | VR ADVISORY SERVICES LTD | 97.4K +— (+0.0%) | 12.8K -7.2K (-36.0%) | 0.00% -0.196 pp | 0.00% -0.003 pp | USD0.27 +1,855.6% | 3 qtrs — |
| 16 | P SCHOENFELD ASSET MANAGEMENT LP | 58.6K +— (+0.0%) | 7.7K -4.3K (-36.0%) | 0.00% -0.118 pp | 0.00% +0.001 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 17 | AVION WEALTH | 54.1K +— (+0.0%) | 7.0K -4.0K (-36.4%) | 0.00% -0.109 pp | 0.00% -0.001 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 18 | SCIENTECH RESEARCH LLC | 51.6K +51.6K (+100.0%) | 6.8K +6.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.004 pp | USD5.28 +0.0% | 3 qtrs — |
| 19 | PERISCOPE CAPITAL INC. | 50.0K +— (+0.0%) | 6.6K -3.7K (-36.0%) | 0.00% -0.101 pp | 0.00% -0.001 pp | USD0.58 +810.3% | 4 qtrs — |
| 20 | CIBC PRIVATE WEALTH GROUP, LLC | 49.1K +— (+0.0%) | 6.5K -3.6K (-36.0%) | 0.00% -0.099 pp | 0.00% +0.000 pp | USD0.21 +2,414.3% | 3 qtrs — |
| 21 | HALLMARK CAPITAL MANAGEMENT INC | 40.0K +— (+0.0%) | 5.3K -3.0K (-36.0%) | 0.00% -0.081 pp | 0.00% 0.000 pp | USD0.27 +1,855.6% | 3 qtrs — |
| 22 | PLATFORM TECHNOLOGY PARTNERS | 37.6K +— (+0.0%) | 5.0K -2.8K (-36.0%) | 0.00% -0.076 pp | 0.00% -0.001 pp | USD0.58 +810.3% | 4 qtrs — |
| 23 | CROSSINGBRIDGE ADVISORS, LLC | 24.3K +— (+0.0%) | 3.2K -4.2K (-56.7%) | 0.00% -0.049 pp | 0.00% -0.003 pp | USD0.21 +2,414.3% | 2 qtrs — |
| 24 | STONEX GROUP INC. | 14.7K +14.7K (+100.0%) | 1.9K +1.9K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.28 +0.0% | 1 qtrs NEW |
| 25 | POINT72 ASSET MANAGEMENT, L.P. | 14.2K +14.2K (+100.0%) | 1.9K +1.9K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.28 +0.0% | 1 qtrs NEW |
| 26 | ALLRED CAPITAL MANAGEMENT, LLC | 11.2K +— (+0.0%) | 1.5K -829.0 (-36.0%) | 0.00% -0.023 pp | 0.00% 0.000 pp | USD0.27 +1,855.6% | 3 qtrs — |
| 27 | FISHER ASSET MANAGEMENT, LLC | 10.0K +10.0K (+100.0%) | 1.3K +1.3K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.28 +0.0% | 1 qtrs NEW |
| 28 | TOWER RESEARCH CAPITAL LLC (TRC) | 9.6K -21.5K (-69.1%) | 1.3K -5.1K (-80.2%) | 0.00% -0.063 pp | 0.00% 0.000 pp | USD0.20 +2,540.0% | 2 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 282.00 +29.0 (+11.5%) | 37.00 -15.0 (-28.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD0.14 +3,671.4% | 3 qtrs — |
| 30 | ADVISOR GROUP HOLDINGS, INC. | 100.00 +— (+0.0%) | 13.00 -7.0 (-35.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs — |
| 31 | COLONY GROUP, LLC | — -12.5K (-100.0%) | — -2.6K (-100.0%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 32 | SOA WEALTH ADVISORS, LLC. | — -2.9K (-100.0%) | — -602.0 (-100.0%) | 0.00% -0.006 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 1.4K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
20.0K
Cash buys
2.00
Cash sales
—
Net activity
-20,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-05 | Fell Donald G. | Director | P-Purchase | D | Common Stock, par value $0.0001 | 10,500 | 0.39 | 4.1K | 20,000 | D | ↗ |
| 2025-06-04 | Fell Donald G. | Director | P-Purchase | D | Common Stock, par value $0.0001 | 9,500 | 0.39 | 3.7K | 9,500 | D | ↗ |
| 2023-08-18 | Wadhwani Avinash R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-18 | PowerUp Sponsor LLC | 10% Owner | S-Sale | D | Class A Ordinary Shares, par value $0.0001 | 4,317,500 | 0.00 | 431.75 | 2,870,000 | — | ↗ |
| 2023-08-18 | PETERSON MICHAEL L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-18 | Fell Donald G. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-18 | Doss Howard A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-18 | Doshi Mayur Mansukhlal | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-18 | AJJARAPU SURENDRA K | Director / Officer / 10% Owner | — | I | Warrants | 6,834,333 | 11.50 | 78.59M | 0 | — | ↗ |
| 2023-05-18 | PowerUp Sponsor LLC | 10% Owner | C-Conversion | D | Class B Ordinary Shares | 7,187,500 | 0.00 | — | 0 | — | ↗ |
| 2022-02-17 | Hack Bruce L. | Director | — | I | Class B Ordinary Shares | 7,187,500 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-96.8K
Shares Outstanding
115.4K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kraig T. Higginson | Interim Chief Executive Officer, President & Executive Chairman of the Board | 342.5K | male |
| Ernest J. Scheidemann Jr. | Chief Financial Officer | 320.0K | male |
| Stephen E. Quesenberry | General Counsel & Corporate Secretary | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ASBP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
